This statistic displays the obesity prevalence in selected European countries by 2025. Great Britain is set to be the most obese nation in Europe by 2025 with an obesity prevalence of **** percent, followed closely by Ireland and Lithuania with an expected prevalence rate of ***** percent respectively.

The National Obesity Audit (NOA) publication series presents a developing set of nationally agreed measures, with the overarching aim to provide a comprehensive picture of activity, access to services and health outcomes of patients using weight management services (WMS) across England. This will allow providers to track, benchmark and improve the quality of these services in future. This release includes data from both Hospital Episode Statistics (HES) for Tier 4 WMS, and the Community Services Data Set (CSDS) for Tier 2 and Tier 3 WMS. More information about WMS tiers can be found on the NOA homepage (see Related Links). Disruption relating to the coronavirus illness (COVID-19) would seem to have affected the quality and coverage of some of our statistics, such as an increase in non-submissions for some datasets. We have also seen some different patterns in the submitted data. For example, fewer patients have been admitted to and discharged from hospital. Therefore, data should be interpreted with care over the COVID-19 period.

By 2025, the prevalence of obese children in Greece is projected to reach **** percent, this would be the highest childhood obesity prevalence across all countries in the EU and the UK. Hungary with **** percent was forecast to have the second-highest prevalence of childhood obesity in Europe, followed by Croatia at **** percent.

According to a 2021 report, Latvia and Estonia both have a ** percent chance of meeting the UN obesity targets for women. Despite this, every country in the EU as well as the UK are deemed to have a very poor chance of reaching the 2025 target set by the United Nations (UN) for halting the rise in obesity. Obesity increases the risk of non-communicable diseases (NCDs). To reduce the burden of NCDs, all the member states of the World Health Assembly had agreed to halt the prevalence of obesity at 2010 levels.

Snapshot img

Weight Management Market Size 2025-2029

The weight management market size is forecast to increase by USD 114.79 billion at a CAGR of 10.9% between 2024 and 2029.

The market is driven by the growing obese population and rising demand for weight management services from developing economies. The increasing prevalence of obesity and related health issues globally presents a significant opportunity for market participants. However, marketing challenges associated with weight management products and services pose a significant hurdle. The stigma surrounding obesity and the perception that weight loss is a personal responsibility rather than a health issue create barriers to market penetration. Health insurance plays a pivotal role in covering costs, while fitness apps and mobile health apps enhance accessibility and tracking.
Companies seeking to capitalize on market opportunities must address these challenges through innovative marketing strategies, affordable pricing, and education initiatives to shift societal perceptions and increase accessibility to weight management services. By focusing on these areas, market participants can effectively navigate challenges and capitalize on the growing demand for weight management solutions. Innovative weight management solutions include waistline control, fitness equipment, surgical equipment, healthy dietary choices, and lifestyle changes.

What will be the Size of the Weight Management Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market for weight management solutions continues to evolve, reflecting the complex and multifaceted nature of weight management and its applications across various sectors. Sleeve gastrectomy and adjustable gastric banding are among the surgical interventions, while anti-obesity medications and pharmacological interventions offer alternative approaches. The prevalence of metabolic syndrome and its associated health risks, including cardiovascular disease and type 2 diabetes, underscores the urgency for sustainable weight loss solutions. Mindful eating, nutrition education, and meal planning are essential components of health behavior modification, while physical fitness and regular exercise routines contribute to weight regain prevention. Fitness and recreational sports centers are offering a wide range of HIIT classes, and HIIT fitness videos are flooding the market.

Hormonal imbalance and stress management are also crucial factors in weight management. The industry is expected to grow by 5.3% annually, driven by the increasing prevalence of obesity and related health issues. For instance, a study showed that patients who underwent bariatric surgery experienced an average weight loss of 30% within the first year. Social media and the young population's hectic lifestyles have led to increased fast food consumption and weight-related health issues, necessitating preventive measures and weight management programs. Additionally, the complexity and cost of weight management solutions can deter potential customers, particularly in developing economies with limited resources.

How is this Weight Management Industry segmented?

The weight management industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Diet
  Equipment
  Services


Distribution Channel

  Offline
  Online


End-user

  Fitness centers and health clubs
  Commercial weight loss centers
  Online weight loss programs
  Slimming centers
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Type Insights

The Diet segment is estimated to witness significant growth during the forecast period. The market is driven by the growing concern over health issues related to visceral fat, weight fluctuation, and obesity. Obesity, characterized by a body mass index (BMI) of 30 or higher, affects over one-third of the global population. This condition can lead to various health complications, including high blood pressure, joint problems, diabetes, and insulin sensitivity issues. To combat these health concerns, weight loss programs focusing on calorie expenditure through diet and physical activity have gained popularity. Diets, specifically, dominate the market, as they offer a more sustainable approach to weight management. Nutritional counseling and micronutrient intake are essential components of effective weight loss programs, ensuring a balanced macronutrient and micronutrient intake. Obesity rates continue to rise, fueling

Prescription Weight Loss Pills Market Outlook

The global prescription weight loss pills market size was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 4.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.1% during the forecast period. This market is driven by a combination of rising obesity rates worldwide, increasing awareness about health and wellness, and a growing preference for pharmaceutical interventions in weight management.

One of the primary growth factors for the prescription weight loss pills market is the escalating prevalence of obesity and overweight individuals globally. According to the World Health Organization (WHO), obesity has nearly tripled since 1975, with over 650 million adults being classified as obese in 2023. This alarming trend has led to increased demand for effective weight loss solutions, including prescription medications. Governments and healthcare organizations are also actively promoting the management of obesity through various initiatives, further boosting market growth.

Another significant growth driver is the advancement in pharmaceutical research and development. The introduction of novel drugs and combination therapies that offer better efficacy and safety profiles is attracting more patients and healthcare providers towards prescription weight loss pills. Additionally, the enhancement of drug delivery systems and the development of personalized medicine approaches are expected to further catalyze market expansion. The increasing investment in clinical trials and FDA approvals for new weight loss medications also play a crucial role in market growth.

The growing awareness about the health risks associated with obesity, such as cardiovascular diseases, diabetes, and certain cancers, is prompting more individuals to seek medical intervention for weight management. The societal shift towards a healthier lifestyle, fueled by the influence of social media and wellness trends, is encouraging people to explore pharmaceutical options for weight loss. Moreover, the stigma associated with obesity is gradually diminishing, making it more acceptable for individuals to seek help, thus increasing the uptake of prescription weight loss pills.

Anorexiants, a class of drugs that suppress appetite, play a crucial role in the prescription weight loss pills market. These medications help individuals reduce their caloric intake by curbing hunger signals, making them an effective tool for managing obesity. The demand for anorexiants is driven by their ability to offer significant weight loss results with relatively manageable side effects. As the market continues to grow, ongoing research is focused on enhancing the efficacy and safety of anorexiants, ensuring they remain a popular choice among healthcare providers and patients seeking pharmaceutical solutions for weight management.

Regionally, North America holds the largest share of the prescription weight loss pills market, driven by high obesity rates, advanced healthcare infrastructure, and strong presence of key market players. Europe follows closely, with significant contributions from countries like the UK, Germany, and France where obesity rates are also high. The Asia Pacific region is expected to witness the fastest growth during the forecast period due to increasing urbanization, changing lifestyles, and rising disposable incomes. Latin America and the Middle East & Africa regions are also anticipated to experience steady growth, driven by improving healthcare access and growing awareness about obesity-related health issues.

Drug Type Analysis

The prescription weight loss pills market is segmented by drug type into appetite suppressants, fat absorption inhibitors, metabolism boosters, and combination drugs. Appetite suppressants are currently the most widely used category, accounting for a significant share of the market. These drugs work by reducing hunger and helping individuals manage their food intake, making them highly popular among patients and healthcare providers. The efficacy of appetite suppressants, coupled with their relatively fewer side effects, makes this segment a key driver of market growth.

Prescription Medicine remains a cornerstone in the battle against obesity, offering structured and medically supervised weight loss

Over the five years through 2025-26, specialist medical practices’ revenue is expected to rise at a compound annual rate of 2.1% to £13 billion. Demand for specialist medical services has been driven by an ageing population and increasing obesity levels, which have elevated health problems like Type 2 diabetes, cardiovascular disease and cancer. These growing problems have prompted the government to raise funding for public healthcare – in June 2025, the government announced £29 billion to support the NHS, with £1.5 billion going to new surgical hubs which will help specialist medical practices reduce wait times and improve the quality of services. Growing waiting lists, partly the result of rising demand and labour shortages, worsen patient health outcomes. Long wait times have encouraged more people to opt for pricey private healthcare, raising revenue and lifting profitability. An agreement between the government and the private sector announced in January 2025 will allow the NHS to purchase additional medical services from private providers when NHS resources are limited. It will take total NHS spend on private operators close to £16 billion in 2025-26, helping ease the pressure of rising demand for public healthcare and driving forecast revenue growth of 1% in 2025-26. Revenue is anticipated to swell at a compound annual rate of 1.4% over the five years through 2030-31 to reach £14 billion. Demand for medical specialists will rise as the UK population ages and obesity rates remain high. That being said, rising health consciousness and government initiatives to reduce obesity may offset demand by encouraging people to lead healthier lifestyles. Medical advances will allow practices to boost productivity and treat more patients. However, addressing workforce shortages in areas like radiology and oncology through recruitment initiatives and investment in training will be essential for the industry to meet rising demand.

The size of the UK Bariatric Surgery Industry market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 6.50% during the forecast period. The UK Bariatric Surgery Industry refers to the sector involved in surgical interventions for obesity; the more extreme cases are handled by surgeons. Bariatric surgery can be defined as general terms used to identify any form of surgery to reduce excessive weight. The surgery technique is manipulative methods in the gut so as to decrease the ingestion of food or block some nutrient uptake. This usually involves bypass stomach resection surgery, adjustable banding surgery among other forms of bariatric surgery. The industry driving this line is the increasing cases of obesity, a complex health issue often related to many chronic diseases like type 2 diabetes, heart disease, and a number of cancers. The NHS stands for the public healthcare service of the UK, so bariatric surgery would be offered to patients who actually qualify based on specific medical criteria, typically those people with a Body Mass Index score of 40 or above or 35 or higher with comorbid related health conditions. More often than not, private clinics are now offering bariatric surgery options for quicker access or procedures not commonly available in the NHS system. Strict regulations of the UK Bariatric Surgery Industry will not cause the lack of care to the high standards in relation to patient needs since it has the body that monitors all of this, like the Care Quality Commission. Increasing rates of obesity, and as it has a continued rise in statistics, this increases those requiring bariatric surgery; in other words, this might be changing the course for the UK within its health horizon. Recent developments include: Dec 2022: Medtronic received CE Mark approval for the Hugo robotic-assisted surgery (RAS) system to be used in general surgery procedures in Europe. The CE Mark for general surgery spans several specialties, including hernia, colorectal, and bariatric surgery., Oct 2022: Researchers at the University College London Hospitals and Imperial College Healthcare NHS Trust were awarded GBP 1.2 million (USD 1.45 million) by the NIHR Efficacy and Mechanism Evaluation program to investigate a minimally invasive procedure called left gastric artery embolization (LGAE).. Key drivers for this market are: Rising Burden of Diabetes and Heart Diseases, Increase in Obesity Among People; Rising Government Initiatives. Potential restraints include: High Cost of Surgery. Notable trends are: Closure Device Segment Expected to Witness a Significant Growth Over the Forecast Period.

According to Cognitive Market Research, the global Non Invasive Fat Reduction market size will be USD 1824.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 16.90% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 675.18 million in 2025 and will grow at a compound annual growth rate (CAGR) of 14.7% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 529.19 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 437.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 18.9% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 69.34 million in 2025 and will grow at a compound annual growth rate (CAGR) of 15.9% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 72.99 million in 2025 and will grow at a compound annual growth rate (CAGR) of 16.2% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 40.15 million in 2025 and will grow at a compound annual growth rate (CAGR) of 16.6% from 2025 to 2033.
Cosmetic centers segment is the fastest growing segment of the Non Invasive Fat Reduction industry

Market Dynamics of Non Invasive Fat Reduction Market

Key Drivers for Non Invasive Fat Reduction Market

Increasing obesity rates and growing aesthetic consciousness among consumers

The global rise in obesity, driven by sedentary lifestyles and unhealthy diets, has significantly increased demand for non-invasive fat reduction solutions. At the same time, heightened aesthetic consciousness fueled by social media, celebrity culture, and workplace appearance standards has made body contouring more mainstream. Consumers now prioritize minimally invasive treatments over surgical options due to lower risks, shorter recovery times, and natural-looking results. This dual trend of rising obesity and beauty awareness is expanding the market, with clinics and medspas offering tailored solutions like Cool Sculpting and ultrasound-based fat reduction to meet diverse patient needs. For instance, in September 2020, Cutera announced the launch of truSculpt Flex, which is the company’s body sculpting platform, in Canada.

https://aesthetics.guidedsolutions.co.uk/news/2020/09/03/cuteras-launches-trusculpt-flex-in-canada/#:~:text=truSculpt%20flex%20is%20Health%20Canada,development%20of%20a%20stronger%20abdomen.

Favorable FDA/CE approvals boosting trust in non-invasive treatments

Regulatory approvals from the FDA (U.S.) and CE (Europe) have played a crucial role in legitimizing non-invasive fat reduction technologies. These certifications assure consumers of safety and efficacy, increasing adoption rates. Brands like CoolSculpting (cryolipolysis) and SculpSure (laser lipolysis) have gained credibility through clinical trials and regulatory backing. As more devices receive approvals, clinics and medspas can confidently market these treatments, attracting a broader customer base. This regulatory trust also encourages innovation, with companies investing in next-gen technologies like AI-assisted body sculpting and energy-based fat reduction systems.

Restraint Factor for the Non Invasive Fat Reduction Market

Potential side effects and variable treatment efficacy deterring some consumers

While non-invasive fat reduction treatments are generally considered safe, some consumers remain hesitant due to potential side effects like temporary redness, swelling, or uneven results. Unlike surgical options, these procedures often require multiple sessions, and outcomes can vary depending on factors like skin type and body composition. This unpredictability makes some people skeptical—after investing time and money, they may not achieve their desired look. Stories of unsatisfactory results circulating online further amplify these concerns. To address this, clinics now emphasize realistic expectations and personalized treatment plans. Still, for those seeking guaranteed, dramatic changes, the appeal of surgical alternatives like liposuction remains strong.

Market Trends in Non Invasive Fat Reduction Market

Increasing demand for personalized body contouring using ...

According to Cognitive Market Research, the global Bariatric Surgical Devices market size will be USD 2,354.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 6.00% from 2025 to 2033.

North America held the major market share for more than 37% of the global revenue with a market size of USD 871.28 million in 2025 and will grow at a compound annual growth rate (CAGR) of 3.8% from 2025 to 2033.
Europe accounted for a market share of over 29% of the global revenue with a market size of USD 682.89 million.
APAC held a market share of around 24% of the global revenue with a market size of USD 565.15 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2033.
South America has a market share of more than 3.8% of the global revenue with a market size of USD 89.48 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2025 to 2033.
Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 94.19 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2033.
Africa had a market share of around 2.2% of the global revenue and was estimated at a market size of USD 51.81 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2033.
Assisting Devices is the fastest growing segment of the Bariatric Surgical Devices industry

Market Dynamics of Bariatric Surgical Devices Market

Key Drivers for Bariatric Surgical Devices Market

Advancements in Minimally Invasive Surgical Technologies Is Expected To Boost Market Growth

The bariatric surgical devices market has witnessed significant growth owing to advancements in minimally invasive surgical (MIS) technologies. These innovations have revolutionized the way weight-loss surgeries are performed, offering patients shorter recovery times, less post-operative pain, reduced scarring, and lower risks of infection. Techniques such as laparoscopic and robotic-assisted surgeries have largely replaced open procedures in developed healthcare systems. Laparoscopic surgery, which involves small incisions and camera-guided instruments, allows for greater surgical precision while minimizing trauma to surrounding tissues. In April 2025, The National Institute for Health and Care Excellence (NICE) approved 11 robotic surgery systems for various procedures, including organ removals and cancer treatments, to be integrated across NHS hospitals. This move aims to reduce patient recovery times and address surgical backlogs.

https://www.thesun.co.uk/health/34509313/robot-surgery-machines-cancer-treatment-nhs”/

Growing Prevalence of Type 2 Diabetes and Hypertension To Boost Market Growth

The rising prevalence of Type 2 diabetes and hypertension is a significant driver of the bariatric surgical devices market. These chronic conditions are closely associated with obesity, which is a key risk factor for their development and progression. As obesity rates surge globally, particularly in urban and aging populations, so does the burden of comorbidities like insulin resistance, high blood pressure, and cardiovascular disease. Bariatric surgery has emerged as a clinically effective intervention not just for weight reduction, but also for the remission or significant improvement of Type 2 diabetes and hypertension in obese patients. Multiple clinical studies have demonstrated that procedures such as gastric bypass and sleeve gastrectomy can lead to long-term improvements or complete resolution of Type 2 diabetes. These surgeries alter the gastrointestinal tract in a way that enhances insulin sensitivity, regulates glucose metabolism, and reduces the need for diabetes medications.

Restraint Factor for the Bariatric Surgical Devices Market

High Cost of Bariatric Surgical Procedures, Will Limit Market Growth

One of the primary restraints affecting the growth of the bariatric surgical devices market is the high cost associated with bariatric surgical procedures. These surgeries such as gastric bypass, sleeve gastrectomy, and adjustable gastric banding can range from $15,000 to $30,000 or more, depending on the country, hospital, and surgeon's expertise. The expense includes not only the surgical procedure itself but also pre-operative evaluations, post-operative care, nutritional counseling, and sometimes lifelong follow-up. In developing countries, th...

This statistic displays individuals with a longstanding illness by gender and body mass index in 2021 in England. In this year, 57 percent of women and 45 percent of men who were classed as obese had at least one longstanding illness.

In the shown time-period the mean height of men and women has generally increased in England. According to the survey, the average height of males rose slightly during the period in consideration, from 174.4 centimeters in 1998 to 176.2 centimeters (approximately 5'9") in 2022. In comparison, the mean height of women was 162.3 centimeters (5'4") in 2022, up from 161 in 1998. Reasons for height increasing While a large part of an adult’s final height is based on genetics, the environment in which a person grows up is also important. Improvements in nutrition, healthcare, and hygiene have seen the average heights increase over the last century, particularly in developed countries. Average height is usually seen as a barometer for the overall health of the population of a country, as the most developed are usually among the ‘tallest’ countries. Average waist circumference also increasing The prevalence of obesity among adults in England has generally been trending upward since 2000. In that year, 21 percent of men and women in England were classified as obese. By 2021, however, this share was 26 percent among women and 25 percent among men. Every adult age group in England had an average BMI which was classified as overweight, apart from those aged 16 to 24, indicating there is a problem with overweightness in England.